Sökning: WFRF:(Vergote M) >
Double-blind, place...
Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)
-
- Kurzeder, Christian (författare)
- Kliniken Essen-Mitte
-
- Bover, Isabel (författare)
- Hospital Son Llàtzer
-
- Marḿe, Frederik (författare)
- University Hospital Heidelberg
-
visa fler...
-
- Rau, Joern (författare)
- Philipp University of Marburg
-
- Pautier, Patricia (författare)
- Institut Gustave Roussy
-
- Colombo, Nicoletta (författare)
- European Institute of Oncology
-
- Lorusso, Domenica (författare)
- Istituto Nazionale dei Tumori
-
- Ottevanger, Petronella (författare)
- Radboud University Nijmegen
-
- Bjurberg, Maria (författare)
- Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Nordic Society of Gynecological Oncology,Skåne University Hospital
-
- Marth, Christian (författare)
- Medical University of Innsbruck
-
- Barretina-Ginesta, Pilar (författare)
- Catalan Institute of Oncology
-
- Vergote, Ignace (författare)
- University Hospitals Leuven
-
- Floquet, Anne (författare)
- Institut Bergoníe
-
- Campo, Josep M Del (författare)
- Vall d'Hebron University Hospital
-
- Mahner, Sven (författare)
- University Medical Center Hamburg-Eppendorf
-
- Bastíere-Truchot, Lydie (författare)
- F. Hoffmann-La Roche AG
-
- Martin, Nicolas (författare)
- F. Hoffmann-La Roche AG
-
- Oestergaard, Mikkel Z. (författare)
- F. Hoffmann-La Roche AG
-
- Kiermaier, Astrid (författare)
- F. Hoffmann-La Roche AG
-
- Schade-Brittinger, Carmen (författare)
- Philipp University of Marburg
-
- Polleis, Sandra (författare)
- Arbeitsgemeinschaft Gynäkologische Onkologie
-
- Bois, Andreas Du (författare)
- Kliniken Essen-Mitte
-
- Gonzalez-Martin, Antonio (författare)
- GEICO
-
visa färre...
-
(creator_code:org_t)
- 2016
- 2016
- Engelska 10 s.
-
Ingår i: Journal of Clinical Oncology. - 0732-183X. ; 34:21, s. 25-2516
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Purpose The AGO-OVAR 2.29/ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-resistant ovarian carcinoma with low tumor human epidermal growth factor receptor 3 (HER3)mRNA expression. We report the results of the primary efficacy analysis. Patients and Methods Eligible patients had ovarian carcinoma that progressed during or within 6 months of completing four or more platinum cycles, centrally tested low tumor HER3 mRNA expression (concentration ratio # 2.81 by quantitative reverse transcriptase polymerase chain reaction on cobas z480 [Roche Molecular Diagnostics, Pleasanton, CA]), and no more than two prior lines of chemotherapy. After investigators selection of the chemotherapy backbone (single-agent topotecan, weekly paclitaxel, or gemcitabine), patientswere randomly assigned to also receive either placebo or pertuzumab (840-mg loading dose followed by 420 mg every 3 weeks). Stratification factors were selected chemotherapy, prior antiangiogenic therapy, and platinum-free interval. The primary end point was independent review committee-assessed progression-free survival (PFS). Additional end points included overall survival, investigator-assessed PFS, objective response rate, safety, patient-reported outcomes, and translational research. Results Overall, 156 patientswere randomly assigned. Adding pertuzumab to chemotherapy did not significantly improve independent review committee-assessed PFS for the primary analysis (stratified hazard ratio, 0.74; 95% CI, 0.50 to 1.11; P = .14; median PFS, 4.3 months for pertuzumab plus chemotherapy v 2.6 months for placebo plus chemotherapy). Sensitivity analyses and secondary efficacy end point results were consistent with the primary analysis. The effect on PFS favoring pertuzumab was more pronounced in the gemcitabine and paclitaxel cohorts. No new safety signals were seen. Conclusion Although the primary objective was not met, subgroup analyses showed trends in PFS favoring pertuzumab in the gemcitabine and paclitaxel cohorts, meriting further exploration of pertuzumab in ovarian cancer.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Kurzeder, Christ ...
-
Bover, Isabel
-
Marḿe, Frederik
-
Rau, Joern
-
Pautier, Patrici ...
-
Colombo, Nicolet ...
-
visa fler...
-
Lorusso, Domenic ...
-
Ottevanger, Petr ...
-
Bjurberg, Maria
-
Marth, Christian
-
Barretina-Ginest ...
-
Vergote, Ignace
-
Floquet, Anne
-
Campo, Josep M D ...
-
Mahner, Sven
-
Bastíere-Truchot ...
-
Martin, Nicolas
-
Oestergaard, Mik ...
-
Kiermaier, Astri ...
-
Schade-Brittinge ...
-
Polleis, Sandra
-
Bois, Andreas Du
-
Gonzalez-Martin, ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of Clini ...
- Av lärosätet
-
Lunds universitet